EVEN-plus syndrome
ee-ven-plus sin-drohm
Also known as: EVEN+ syndrome, HSPA9-related disorder
At a Glance
What is EVEN-plus syndrome?
EVEN-plus syndrome is a rare genetic disorder that affects multiple body systems, primarily the skeletal and muscular systems. It is caused by mutations in the HSPA9 gene, which plays a crucial role in cellular stress responses. Over time, individuals with this condition may experience progressive skeletal deformities and muscle weakness. Early symptoms often include delayed growth and developmental milestones, while later symptoms can involve more severe skeletal abnormalities and potential organ involvement. Early diagnosis is critical to manage symptoms and improve quality of life. The condition can place a significant emotional and financial burden on families due to the need for ongoing medical care and support. Prognosis varies, but many individuals can lead fulfilling lives with appropriate interventions. Daily life may involve regular medical appointments, physical therapy, and adaptive equipment to assist with mobility. Family support and genetic counseling are important aspects of managing the condition. Research is ongoing to better understand the syndrome and develop targeted treatments. Despite the challenges, many affected individuals and families find ways to adapt and thrive.
Medical Definition
EVEN-plus syndrome is characterized by congenital malformations and skeletal dysplasia resulting from mutations in the HSPA9 gene. Pathologically, these mutations disrupt the function of mortalin, a protein involved in mitochondrial iron-sulfur cluster biogenesis, leading to cellular dysfunction. Histological findings may reveal abnormal bone and muscle tissue development. The syndrome is classified under genetic disorders with autosomal recessive inheritance. Epidemiologically, it is an extremely rare condition with a prevalence of approximately 1 in 1,000,000. The disease course involves progressive skeletal abnormalities and potential multi-system involvement, necessitating comprehensive medical management.
EVEN-plus syndrome Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Skeletal dysplasia in EVEN-plus syndrome manifests as abnormal bone growth and development, leading to short stature and joint deformities. This is caused by mutations in the HSPA9 gene, affecting the function of mortalin, which is crucial for cellular stress responses and mitochondrial function. Over time, skeletal abnormalities can worsen, potentially leading to mobility issues and chronic pain. Daily life is impacted by physical limitations, and management includes physical therapy and orthopedic interventions to improve mobility and quality of life.
Congenital malformations are present at birth and can include a variety of structural anomalies such as heart defects or cleft palate. These malformations result from disrupted embryonic development due to genetic mutations affecting cellular processes. As the individual grows, these malformations may require surgical correction or ongoing medical management. They can significantly impact daily life by affecting physical appearance and function, necessitating multidisciplinary medical care.
Developmental delay is characterized by slower achievement of developmental milestones such as walking or talking. This delay is linked to the dysfunction of the HSPA9 gene, which plays a role in cellular stress responses and mitochondrial health. The delay may become more apparent as the child grows, potentially leading to learning difficulties and social challenges. Early intervention with therapies such as speech and occupational therapy can help improve developmental outcomes and support daily functioning.
Common
Hypotonia, or decreased muscle tone, presents as muscle weakness and reduced resistance to passive movement. It is caused by impaired mitochondrial function due to HSPA9 mutations, affecting muscle energy metabolism. Over time, hypotonia can lead to delays in motor skills and difficulties with posture and movement. Daily life is impacted by challenges in physical activities, and management includes physical therapy to strengthen muscles and improve motor skills.
Growth retardation is observed as a slower rate of growth compared to peers, resulting in shorter stature. This is due to the disrupted function of cellular processes involved in growth and development, linked to HSPA9 gene mutations. As the child ages, growth retardation becomes more pronounced, potentially affecting self-esteem and social interactions. Regular monitoring and nutritional support can help manage growth issues and improve overall health.
Facial dysmorphism includes distinctive facial features such as a flat nasal bridge or wide-set eyes. These features arise from abnormal craniofacial development due to genetic mutations affecting cellular growth. The dysmorphic features remain consistent over time and can be a key diagnostic indicator. While they do not typically impact health, they may affect social interactions, and counseling can support self-esteem and social adaptation.
Less Common
Cardiac anomalies can include structural heart defects such as septal defects or valve abnormalities. These arise from disrupted cardiac development during embryogenesis due to genetic mutations. Over time, cardiac anomalies may lead to complications such as heart failure or arrhythmias if not managed. Regular cardiac evaluations and, if necessary, surgical interventions are crucial for maintaining heart health and preventing complications.
Hearing loss in EVEN-plus syndrome can range from mild to severe and is often sensorineural in nature. It results from the dysfunction of auditory pathways due to mitochondrial impairment linked to HSPA9 mutations. Hearing loss may progress over time, affecting communication and language development. Early detection and intervention with hearing aids or cochlear implants can significantly improve communication abilities and quality of life.
What Causes EVEN-plus syndrome?
EVEN-plus syndrome is caused by mutations in the HSPA9 gene, located on chromosome 5q31.1. The HSPA9 gene encodes mortalin, a heat shock protein that plays a crucial role in mitochondrial function and cellular stress response. Specific mutations in HSPA9 disrupt the protein's ability to maintain mitochondrial integrity and assist in the folding of nascent proteins. These mutations lead to impaired mitochondrial iron-sulfur cluster biogenesis, which is essential for electron transport and energy production. Dysfunctional mitochondria result in reduced ATP production and increased oxidative stress, affecting cellular metabolism. The accumulation of damaged mitochondria triggers a cascade of cellular stress responses, including the activation of pro-inflammatory pathways. Neuroinflammation is exacerbated by the release of cytokines and other inflammatory mediators, contributing to neuronal damage. White matter degeneration occurs due to the loss of oligodendrocytes, which are particularly sensitive to mitochondrial dysfunction. The pattern of symptoms, including skeletal dysplasia and congenital malformations, arises from the differential vulnerability of tissues to mitochondrial dysfunction during development. Variability in disease severity among patients is influenced by the specific nature of the HSPA9 mutations and the presence of modifying genetic or environmental factors. The immune response may further exacerbate tissue damage, leading to a progressive decline in function. In some cases, compensatory mechanisms may partially mitigate the effects of mitochondrial dysfunction, delaying symptom onset. The interplay between mitochondrial dysfunction and immune activation highlights the complex pathophysiology of EVEN-plus syndrome. Understanding these mechanisms is crucial for developing targeted therapies to alleviate symptoms and improve patient outcomes.
How is EVEN-plus syndrome Diagnosed?
Typical age of diagnosis: EVEN-plus syndrome is typically diagnosed in early childhood when congenital malformations and skeletal dysplasia become apparent. Diagnosis often occurs after parents notice developmental delays or physical abnormalities. Early genetic counseling and testing are crucial for families with a history of the condition. Diagnosis can also occur prenatally if there is a known familial mutation.
Clinicians look for characteristic features such as skeletal dysplasia, congenital malformations, and developmental delays. A detailed family history is important to identify potential genetic links. Physical examination may reveal limb abnormalities, facial dysmorphisms, or other systemic anomalies. This step helps narrow down the differential diagnosis and indicates the need for further genetic testing.
X-rays and MRI are commonly used imaging modalities to assess skeletal abnormalities. Specific abnormalities such as bone dysplasia or joint malformations are visible. Imaging findings support the clinical diagnosis by confirming skeletal involvement. Differential diagnoses like other forms of skeletal dysplasia can be excluded based on imaging characteristics.
Blood tests may be ordered to assess metabolic function and rule out other conditions. Biomarkers such as mitochondrial dysfunction indicators may be sought. Abnormal results might include elevated lactate levels or iron-sulfur cluster deficiencies. These results guide the clinician towards considering genetic testing for confirmation.
The HSPA9 gene is sequenced to identify pathogenic mutations. Mutations such as compound heterozygous variants are typically found. Genetic test results confirm the diagnosis of EVEN-plus syndrome by identifying specific mutations. These results are crucial for family counseling and assessing the risk of recurrence in future pregnancies.
EVEN-plus syndrome Treatment Options
Iron chelators are used to manage mitochondrial dysfunction by reducing iron overload. These drugs work by binding excess iron and facilitating its excretion. Specific drugs like deferiprone or deferasirox may be used based on clinical evidence of efficacy in related conditions. Clinical trials have shown some improvement in mitochondrial function with these agents. Limitations include potential side effects like agranulocytosis and gastrointestinal disturbances.
Techniques such as joint mobilization and muscle strengthening exercises are employed. The therapeutic goal is to improve mobility and reduce discomfort associated with skeletal abnormalities. Sessions are typically conducted twice a week for several months. Measurable outcomes include increased range of motion and improved functional abilities. Long-term benefits include enhanced quality of life and reduced need for surgical interventions.
Surgery is indicated for severe skeletal deformities causing functional impairment. The procedure involves cutting and realigning bones to correct deformities. Expected benefits include improved limb function and pain reduction. Surgical risks include infection, nerve damage, and the need for revision surgery. Post-operative care requires physical therapy and regular follow-up to monitor healing and function.
The care team includes geneticists, orthopedic surgeons, physical therapists, and psychologists. Interventions focus on comprehensive management of symptoms and improving quality of life. Psychosocial support strategies involve counseling and support groups for patients and families. Family education is provided on disease management and genetic implications. Long-term monitoring includes regular assessments to adjust treatment plans as needed.
When to See a Doctor for EVEN-plus syndrome
- Severe respiratory distress — this is an emergency because it can lead to life-threatening oxygen deprivation.
- Acute chest pain — this could indicate serious cardiovascular complications requiring immediate attention.
- Sudden loss of consciousness — this is critical as it may signify a severe neurological event.
- Persistent high fever — this could indicate an underlying infection or inflammatory process that needs medical evaluation.
- Unexplained weight loss — significant weight loss may suggest metabolic or systemic issues requiring further investigation.
- Progressive muscle weakness — this may indicate worsening of the condition and should prompt a medical review.
- Mild fatigue — monitor energy levels and ensure adequate rest and nutrition.
- Intermittent joint pain — keep track of pain episodes and manage with over-the-counter pain relief if necessary.
EVEN-plus syndrome — Frequently Asked Questions
Is this condition hereditary?
EVEN-plus syndrome is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition. De novo mutations are rare but possible. Carrier status can have implications for family planning, and genetic counseling is recommended for affected families to understand the risks and options.
What is the life expectancy for someone with this condition?
Life expectancy varies depending on the severity and age of onset of EVEN-plus syndrome. Early diagnosis and appropriate management can improve outcomes, while complications such as respiratory issues can worsen prognosis. Mortality is often related to severe organ dysfunction or infection. Treatment can extend survival and improve quality of life, but realistic expectations should be set based on individual health status. Regular follow-up with healthcare providers is essential to manage the condition effectively.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis of EVEN-plus syndrome typically involves genetic testing, such as exome sequencing, to identify mutations in the HSPA9 gene. The time from first symptoms to diagnosis can vary, often taking months to years due to the rarity of the condition. Patients are usually referred to geneticists or specialists in rare diseases. Delays in diagnosis are common due to the overlap of symptoms with other conditions. Confirmation is achieved through genetic testing and clinical evaluation of symptoms.
Are there any new treatments or clinical trials available?
Research is ongoing to better understand the genetic basis and potential treatments for EVEN-plus syndrome. Gene therapy and other novel approaches are being explored, though they are not yet widely available. Clinical trials can be found on ClinicalTrials.gov by searching for EVEN-plus syndrome or related genetic studies. Patients should discuss with their doctors the possibility of participating in trials. New treatments may take several years to become available, depending on research progress.
How does this condition affect daily life and activities?
EVEN-plus syndrome can significantly impact mobility and self-care, depending on the severity of skeletal dysplasia and other symptoms. Educational needs may be affected, requiring specialized support. Social and emotional challenges are common, and psychological support can be beneficial. The condition can place a significant burden on families, necessitating access to resources and support networks. Adaptations such as mobility aids and educational accommodations can greatly assist in daily living.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.A new phenotype of EVEN-PLUS syndrome in a Chinese family and literature review.
Liu M, Li H, Ren S et al. · Mol Genet Genomic Med · 2024 · PMID: 38284453
- 2.Biophysical Consequences of EVEN-PLUS Syndrome Mutations for the Function of Mortalin.
Moseng MA, Nix JC, Page RC · J Phys Chem B · 2019 · PMID: 30933555
- 3.Identifying patients with EVEN-plus syndrome using exome sequencing and clinical feature analysis: A case report.
Li HW, Ma BX, Kong YM et al. · Mol Genet Genomic Med · 2022 · PMID: 36052765
- 4.EVEN-PLUS syndrome: A case report with novel variants in HSPA9 and evidence of HSPA9 gene dysfunction.
Younger G, Vetrini F, Weaver DD et al. · Am J Med Genet A · 2020 · PMID: 32869452
- 5.Prenatal to preimplantation genetic diagnosis of a novel compound heterozygous mutation in HSPA9 associated with Even-Plus syndrome.
Chang X, Ji C, Zhang T et al. · Clin Chim Acta · 2024 · PMID: 38281662
- 6.Mutations in the heat-shock protein A9 (HSPA9) gene cause the EVEN-PLUS syndrome of congenital malformations and skeletal dysplasia.
Royer-Bertrand B, Castillo-Taucher S, Moreno-Salinas R et al. · Sci Rep · 2015 · PMID: 26598328
- 7.Mitochondrial iron-sulfur cluster biogenesis from molecular understanding to clinical disease.
Alfadhel M, Nashabat M, Abu Ali Q et al. · Neurosciences (Riyadh) · 2017 · PMID: 28064324
- 8.Bioinformatics analysis of Rickettsia typhi autoimmune associations and screening of Streptomyces-derived inhibitors.
Basharat Z, Ogaly HA, Al-Zahrani FAM et al. · BioData Min · 2025 · PMID: 41316447
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-18